ArticleCell chemical biology2018
Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions.
Article in Cell chemical biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 1 synthesis or guideline pooled it, 167 citations in OpenAlex.
- Exploiting meta-analysis of genome-wide interaction with serum 25-hydroxyvitamin D to identify novel genetic loci associated with pulmonary function.The American journal of clinical nutrition · 2024Pooled it
- TechBio 3.0 closes the drug discovery loop with multimodal AI and generative chemistry.npj drug discovery · 2026Review
- Bridging the phenotype-target gap for molecular generation via multi-objective reinforcement learning.Bioinformatics (Oxford, England) · 2026Article
- LEP-AD: language embedding of proteins and attention to drugs predicts drug-target interactions.Journal of cheminformatics · 2026Article
- Targeting protein protein interactions and their modulators to enable new therapeutic strategies for human diseases.NPJ systems biology and applications · 2026Review
- Pan-cancer gene signature analysis of macrophage polarization and compound prediction for reprogramming tumor-associated macrophages toward M1-like macrophages.Cancer pathogenesis and therapy · 2026Article
- Integrating artificial intelligence and manual curation to enhance bioassay annotations in ChEMBL.Journal of cheminformatics · 2026Article
- PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer.Research square · 2026Article
- Gene4Denovo2: an updated platform for human de novo mutations discovery and interpretation.Nucleic acids research · 2026Article
- Artificial Intelligence Revolution in Pharmaceutical Sciences : Advancements, Clinical Impacts, and Applications.Current pharmaceutical biotechnology · 2026Review
- Systems Analysis of miRNA-Mediated Host Regulatory Response in HPV-Associated Cervical Malignancy.Computational and structural biotechnology journal · 2026Article
- Multi agent large language models for biomedical hypothesis generation in drug combination discovery.iScience · 2025Article
- Translational Informatics Driven Drug Repositioning for Neurodegenerative Disease.Current neuropharmacology · 2025Review
- Drug target affinity prediction based on multi-scale gated power graph and multi-head linear attention mechanism.PloS one · 2025Article
- Improving drug-target affinity prediction by adaptive self-supervised learning.PeerJ. Computer science · 2025Article
- Simulate Scientific Reasoning with Multiple Large Language Models: An Application to Alzheimer's Disease Combinatorial Therapy.medRxiv : the preprint server for health sciences · 2024Article
- High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity.Nature medicine · 2024Article
- The changing scenario of drug discovery using AI to deep learning: Recent advancement, success stories, collaborations, and challenges.Molecular therapy. Nucleic acids · 2024Review
- Decoding the Foodome: Molecular Networks Connecting Diet and Health.Annual review of nutrition · 2024Review
- Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling.Oncogenesis · 2024Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 5 institutions in 3 countries.
Funding
Abstract
Knowledge of the full target space of bioactive substances, approved and investigational drugs as well as chemical probes, provides important insights into therapeutic potential and possible adverse effects. The existing compound-target bioactivity data resources are often incomparable due to non-standardized and heterogeneous assay types and variability in endpoint measurements. To extract higher value from the existing and future compound target-profiling data, we implemented an open-data web platform, named Drug Target Commons (DTC), which features tools for crowd-sourced compound-target bioactivity data annotation, standardization, curation, and intra-resource integration. We demonstrate the unique value of DTC with several examples related to both drug discovery and drug repurposing applications and invite researchers to join this community effort to increase the reuse and extension of compound bioactivity data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.